Giovanni Randon, MD

Videos

Relationship Between Clinicopathological Features and Immunotherapy Benefit Among Patients With dMMR/MSI-High Metastatic or Unresectable Gastric Cancer

08/17/2023

Giovanni Randon , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Giovanni Randon, MD, presented results from a study relating clinicopathological features and immunotherapy benefit among patients with dMMR/MSI-high metastatic or unresectable gastric...

At the 2023 World Congress on...

08/17/2023

Oncology

Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)

Encorafenib plus cetuximab is a standard option in the treatment of BRAFV600E mut mCRC pts pre-treated with at least one systemic therapy. RNF43 is a negative regulator of WNT pathway. A ...

Guglielmo Vetere ;

G. Fontanini ;

Rodrigo De Almeida Toledo ;

F. Bergamo ;

Giovanni Randon , MD;

Simone Oldani ;

Walter Ferrari Bravo ;

Gianmarco Ricagno ;

Paola Vignali ;

Sara Lonardi ;

E. Elez ;

R. Moretto ;